Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study
Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan. The study data will be used to support a New Drug Application (NDA) for TLX591-Px in Japan. MELBOURNE, Australia and...